Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATR - phosphoproteomics - DHX9 validation HeLa

ABSTRACT: Validation of the phosphorylation of S321 in DHX9 by ATR. Samples: (A): Hydroxyurea + ATR inhibitor treated; (C) Hydroxyurea + Chk1 inhibitor treated; (H): Hydroxyurea treated.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: John Rouse

PROVIDER: PXD050953 | JPOST Repository | Thu Apr 11 00:00:00 BST 2024

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	FL_20240308_Rathan_JR_A1.mzML	Mzml
	FL_20240308_Rathan_JR_A1.raw	Raw
	FL_20240308_Rathan_JR_A2.mzML	Mzml
	FL_20240308_Rathan_JR_A2.raw	Raw
	FL_20240308_Rathan_JR_A3.mzML	Mzml

Items per page:

1 - 5 of 20

Similar Datasets

ATR - phosphoproteomics - DHX9 validation HEK293

Project description:Validation of the phosphorylation of S321 in DHX9 by ATR. Samples: (A): Hydroxyurea + ATR inhibitor treated; (C) Hydroxyurea + Chk1 inhibitor treated; (H): Hydroxyurea treated.

2024-04-11 | PXD050954 | JPOST Repository

ATR phosphoproteomics - substrate validation

Project description:ATR phosphoproteomics - Validation of ATR substrates as identified in phosphoproteomics screen. Sample Processing Protocol: Samples were processed as detailed in the accompanying manuscript. Data Processing Protol: Data were processed as detailed in the accompanying manuscript and the attached R script files.

2024-01-16 | PXD040476 | JPOST Repository

Phosphoproteomics of ATR Signaling in Prophase I of Mouse Meiosis

Project description:Here we used phosphoproteomics to define meiosis-specific ATR signaling events during prophase I in mice following chemical and genetic ablation of ATR signaling. Quantitative analysis of phosphoproteomes obtained after tissue-specific genetic ablation of the ATR activating 9-1-1 complex or treatment with ATR inhibitor revealed over 49,800 phosphorylation sites from testes samples, of which 401 phosphorylation sites were found to be dependent on both the 9-1-1 complex and ATR kinase.

2021-01-25 | MSV000086764 | MassIVE

Substrates of the ATR kinase - Phosphoproteomics

Project description:Identification and validation of substrates of the ATR kinase by quantitative phosphoproteomics

2024-01-15 | PXD041250 | Pride

The effect of ATR inhibition on the replication timing program

Project description:As a part of the project looking into the role of ATR in regulating replication initiation, we report the replication timing analysis of the U2OS cells treated with ATR kinase inhibitor AZD6738

2019-07-26 | GSE131018 | GEO

The effect of ATR inhibition on the replication timing program

Project description:as a part of the project looking into the role of ATR in regulating replication initiation and to investigate the rapid replication of CD8+ T cells, we report the replication timing analysis of murine CD8+ T cells and fibroblasts treated with ATR kinase inhibitor AZD6738

2022-05-01 | GSE183412 | GEO

RNA-seq of human neuroblastoma cell lines treated with the ATR inhibitor BAY 1895344

Project description:To characterize the downstream gene expression response following ATR inhibition, we performed RNA-Seq after treatment of CLB-BAR and CLB-GE neuroblastoma cells with 50 nM of the ATR inhibitor BAY 1895344 for 24h and 48h

2021-10-21 | E-MTAB-10603 | biostudies-arrayexpress

SETD2 loss and ATR inhibition synergistically promote cGAS signaling and immunotherapy response in renal cell carcinoma

Project description:Immune checkpoint blockade (ICB) demonstrates durable clinical benefit only in a minority of renal cell carcinoma (RCC) patients. Identifying molecular features that determine response and developing approaches to enhance the response remain an urgent clinical need. Here we found that, in multiple RCC cell lines, targeting the ATR-CHK1 axis with pharmacological inhibitors increased cytosolic DNA accumulation, activated the cGAS-IRF3-dependent cytosolic DNA sensing pathway, and resulted in the inflammatory cytokine expression. SETD2 mutated RCC cell lines or tumor samples were associated with preferential ATR-CHK1 activation over ATM-CHK2 activation. SETD2 knockdown promoted the cytosolic DNA sensing pathway and conferred greater sensitivity in response to ATR-CHK1 inhibition. In murine Renca tumors, Setd2 knockdown and ATR inhibitor VE822 synergistically promoted cytosolic DNA sensing pathway, immune cell infiltration, and immune checkpoint protein expression. Setd2 deficient Renca tumors demonstrated greater vulnerability to ICB monotherapy or in combination with VE822 than Setd2 proficient tumors. SETD2 mutations were associated with a higher response rate and prolonged overall survival in ICB-treated RCC patients, but not in non-ICB-treated RCC patients. This study provides a mechanism-based guidance to develop more personalized combination therapy regimens for RCC patients with SETD2 mutations.

2023-07-25 | GSE234732 | GEO

RNA-seq of neuroblastoma mice models after treatment with the ATR inhibitor BAY 1895344

Project description:To understand the in vivo transcriptomic response to ATR inhibition, RNA-Seq was performed after treatment of 2 previously developed neuroblastoma mouse models (Alk-F1178S;Th-MYCN and Rosa26_Alkal2;Th-MYCN; see Borenas et al., EMBO J, 2021) with the ATR inhibitor BAY 1895344.

2021-10-21 | E-MTAB-10616 | biostudies-arrayexpress